The findings that the VDAC1‐based N‐Ter‐Antp, Antp‐LP4, Tf‐LP4, and, particularly, the protease‐protected D‐version of the peptides (Figs 1, 2, 3) efficiently killed such varied cancer cells, regardless of the cell mutation status, provide the opportunity for developing new therapies for different cancers. Here, HOXA7 is linked to cancer.